Pharmaids Pharmaceuticals Limited Stock Price Today (NSE: PHARMAID)
Fundamental Score
Pharmaids Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Pharmaids Pharmaceuticals Limited share price today is ₹27.67, down 6.17% on NSE/BSE as of 30 March 2026. Pharmaids Pharmaceuticals Limited (PHARMAID) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹155.46 (Cr). The 52-week high for PHARMAID share price is ₹73.45 and the 52-week low is ₹29.05. The company has a Return on Equity (ROE) of -16.29% and a debt-to-equity ratio of 0.39.
Pharmaids Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Pharmaids Pharmaceuticals Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Pharmaids Pharmaceuticals Share Price: A Financial Stability Analysis
The pharmaceutical industry, often viewed as recession-resistant due to consistent demand for healthcare products, faces increasing pressure on pricing and profitability. This analysis evaluates the financial stability of Pharmaids Pharmaceuticals based on publicly available data. Currently, the Pharmaids Pharmaceuticals share price stands at ₹39.220001. A key indicator of potential concern is the absence of a Price-to-Earnings (PE) ratio, which often suggests the company isn't currently profitable. Furthermore, the Return on Capital Employed (ROCE) figure of -17.43% warrants close scrutiny.
A negative ROCE of -17.43% indicates that Pharmaids Pharmaceuticals is not generating profits from its capital investments. This impacts the company's "moat," or competitive advantage, by hindering its ability to reinvest in research and development, expand production capacity, or acquire new technologies. A strong moat is crucial for long-term sustainability in the competitive pharmaceutical landscape. This figure suggests Pharmaids Pharmaceuticals may struggle to maintain its market position against competitors with healthier returns.
When compared to sector peers, the concerns surrounding Pharmaids Pharmaceuticals become more apparent. For example, consider
Mankind Pharma Ltd. While a direct comparison requires deeper analysis of management strategies and capital allocation, generally speaking, companies like Mankind Pharma Ltd often demonstrate superior resource management and operational efficiency, reflecting positively in their financial metrics. These observations don't constitute a direct evaluation of either company's management, but rather a comparison of their overall financial positions based on publicly available data.This financial analysis of Pharmaids Pharmaceuticals share price forms part of a comprehensive 80-parameter fundamental audit. The audit is verified by Sweta Mishra, and employs a range of analytical techniques to assess the company’s long-term viability. This examination highlights areas of potential financial weakness that require further investigation. This analysis is purely observational and should not be construed as investment advice. It is based on the limited data available at the time of assessment.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Pharmaids Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PHARMAID across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Strong Revenue Growth (64.31%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-16.29%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-17.43%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-171.97%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (-5.17x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Pharmaids Pharmaceuticals Limited Financial Statements
Comprehensive financial data for Pharmaids Pharmaceuticals Limited including income statement, balance sheet and cash flow
About PHARMAID (Pharmaids Pharmaceuticals Limited)
Pharmaids Pharmaceuticals Limited is a dynamic and innovative force within the global pharmaceutical landscape, dedicated to pioneering advancements in healthcare through cutting-e...dge research, development, and manufacturing. With an unwavering commitment to improving patient lives, Pharmaids leverages its state-of-the-art facilities and a team of highly skilled scientists and engineers to create a diverse portfolio of high-quality pharmaceutical products. The company's core values revolve around integrity, quality, and innovation, driving its relentless pursuit of excellence in every aspect of its operations. Pharmaids's strong emphasis on research and development allows it to stay at the forefront of emerging therapeutic areas and deliver innovative solutions to unmet medical needs. At the heart of Pharmaids' operations lies a dedication to meeting the evolving needs of its customers and partners. The company boasts a comprehensive suite of services, encompassing custom synthesis, process development, and large-scale manufacturing. Pharmaids' commitment to quality is evident in its adherence to stringent regulatory standards and its implementation of robust quality control measures throughout the manufacturing process. With a global reach, Pharmaids serves a diverse clientele, including leading pharmaceutical companies, research institutions, and healthcare providers. Its collaborative approach and customer-centric focus ensure that its partners receive tailored solutions that meet their specific requirements, driving mutual success and long-term partnerships. Pharmaids Pharmaceuticals Limited distinguishes itself through its unwavering focus on sustainability and social responsibility. The company is committed to minimizing its environmental impact through the implementation of eco-friendly practices and the responsible use of resources. Pharmaids also actively engages in community outreach programs, supporting initiatives that promote health and education in underserved populations. By integrating sustainability and social responsibility into its core business practices, Pharmaids strives to create a positive impact on both the environment and the communities in which it operates. This commitment reflects the company's belief that business success and social progress are intrinsically linked.
Company Details
Key Leadership
Latest News
PHARMAID Share Price: Frequently Asked Questions
What is the current share price of Pharmaids Pharmaceuticals Limited (PHARMAID)?
As of 30 Mar 2026, 12:05 pm IST, Pharmaids Pharmaceuticals Limited share price is ₹27.67. The PHARMAID stock has a market capitalisation of ₹155.46 (Cr) on NSE/BSE.
Is PHARMAID share price Overvalued or Undervalued?
PHARMAID share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Pharmaids Pharmaceuticals Limited stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of PHARMAID share price?
The 52-week high of PHARMAID share price is ₹73.45 and the 52-week low is ₹29.05. These values are updated daily from NSE/BSE price data.
What factors affect the Pharmaids Pharmaceuticals Limited share price?
Key factors influencing PHARMAID share price include quarterly earnings growth (Sales Growth: 64.31%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Pharmaids Pharmaceuticals Limited a good stock for long-term investment?
Pharmaids Pharmaceuticals Limited shows a 5-year Profit Growth of N/A% and an ROE of -16.29%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.39 before investing in PHARMAID shares.
How does Pharmaids Pharmaceuticals Limited compare with its industry peers?
Pharmaids Pharmaceuticals Limited competes with major peers in the Pharmaceuticals. Investors should compare PHARMAID share price P/E of 0.00x and ROE of -16.29% against the industry averages to determine competitive standing.
What is the P/E ratio of PHARMAID and what does it mean?
PHARMAID share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is PHARMAID performing according to Bull Run's analysis?
PHARMAID has a Bull Run fundamental score of 8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does PHARMAID belong to?
PHARMAID operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Pharmaids Pharmaceuticals Limited share price.
What is Return on Equity (ROE) and why is it important for PHARMAID?
PHARMAID has an ROE of -16.29%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Pharmaids Pharmaceuticals Limited generates profits from shareholders capital.
How is PHARMAID debt-to-equity ratio and what does it indicate?
PHARMAID has a debt-to-equity ratio of 0.39, which indicates moderate leverage that should be monitored.
What is PHARMAID dividend yield and is it a good dividend stock?
PHARMAID offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Pharmaids Pharmaceuticals Limited shares.
How has PHARMAID share price grown over the past 5 years?
PHARMAID has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in PHARMAID and why does it matter?
Promoters hold 32.99% of PHARMAID shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Pharmaids Pharmaceuticals Limited.
What is PHARMAID market capitalisation category?
PHARMAID has a market capitalisation of ₹155 crores, placing it in the Small-cap category.
How volatile is PHARMAID stock?
PHARMAID has a beta of N/A. A beta > 1 suggests the Pharmaids Pharmaceuticals Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is PHARMAID operating profit margin trend?
PHARMAID has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is PHARMAID quarterly performance?
Recent quarterly performance shows Pharmaids Pharmaceuticals Limited YoY Sales Growth of 64.31% and YoY Profit Growth of -171.97%.
What is the institutional holding pattern in PHARMAID?
PHARMAID has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Pharmaids Pharmaceuticals Limited stock.